Rock Springs Capital Management LP increased its stake in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 775,131 shares of the company's stock after buying an additional 18,200 shares during the quarter. Rock Springs Capital Management LP owned about 1.48% of Pharvaris worth $14,859,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of Pharvaris by 3.6% in the 4th quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after purchasing an additional 189,714 shares during the last quarter. State Street Corp acquired a new position in Pharvaris in the 3rd quarter valued at $1,000,000. Geode Capital Management LLC increased its stake in Pharvaris by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company's stock valued at $735,000 after buying an additional 1,356 shares during the period. Jane Street Group LLC acquired a new stake in shares of Pharvaris in the 3rd quarter worth $526,000. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of Pharvaris in the fourth quarter valued at about $196,000.
Analysts Set New Price Targets
Separately, JMP Securities upped their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Friday, January 31st.
Check Out Our Latest Stock Analysis on Pharvaris
Pharvaris Stock Performance
NASDAQ:PHVS traded down $0.27 during mid-day trading on Wednesday, hitting $14.82. 22,087 shares of the company's stock traded hands, compared to its average volume of 68,761. The company has a market cap of $774.94 million, a PE ratio of -5.29 and a beta of -2.84. The firm's 50 day simple moving average is $14.97 and its 200 day simple moving average is $18.12. Pharvaris has a 1 year low of $11.51 and a 1 year high of $25.50.
Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Monday, April 7th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.06. On average, research analysts expect that Pharvaris will post -2.71 earnings per share for the current fiscal year.
Pharvaris Company Profile
(
Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
